Skip to main content
. 2014 Apr 16;5(3):167–175. doi: 10.1136/flgastro-2014-100441

Table 2.

Crohn's disease activity, faecal calprotectin levels and subsequent clinical outcomes

Crohn's disease activity Mean faecal calprotectin (mcg/g)
(SEM)
Number Symptomatic at assessment (%) Mean duration of review (months)
(SEM)
Subsequent escalation of treatment (%)
Medical Surgical
Quiescent 105 (19) 19 0 16.5 (2.4) 0 5
Mild 282 (71) 14 0 11.7 (2.5) 14 7
Moderate 611 (80) 14 54 7.5 (1.6) 43 14
Severe 1314 (224) 24 100 9.5 (1.5) 54 25